MAPT and Alzheimer disease: Our group has previously detected increased plasma levels of Aβ42, total and p-tau T181 in patients with AD, and increased plasma α-synuclein in patients with PD compared to controls using an immuno-magnetic reduction method (IMR) [10,11,14].